Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: G-BA's Glybera assessment in line with uniQure's expectations

    Germany's Federal Joint Committee (G-BA) issued a final benefit assessment stating that the additional benefit was not quantifiable from gene therapy Glybera alipogene tiparvovec from uniQure N.V. (NASDAQ:QURE) to treat…

    Published on 5/21/2015
  • COMPANY NEWS: China Medical Systems licenses Traumakine from Faron

    China Medical Systems Holding Ltd. (HKSE:867) licensed rights in greater China to develop and commercialize Traumakine (FP-1201) from Faron Pharmaceuticals Ltd. (Turku, Finland). This year, Faron expects to start a …

    Published on 5/20/2015
  • COMPANY NEWS: FDA narrows breakthrough designation for BMS HCV combo

    Bristol-Myers Squibb Co. (NYSE:BMY) said a combination of its daclatasvir (BMS-790052) and Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) received an amended breakthrough therapy designation from FDA to …

    Published on 5/20/2015
  • COMPANY NEWS: Management tracks

    Amgen Inc. (NASDAQ:AMGN) hired Jonathan Graham as SVP and general counsel, effective July 13. He will succeed David Scott, who is retiring. Graham was SVP and general counsel at Danaher Corp. (NYSE:DHR).Cannabinoid …

    Published on 5/20/2015
  • COMPANY NEWS: bluebird outlines accelerated pathways for LentiGlobin BB305

    bluebird bio Inc. (NASDAQ:BLUE) gained $14.13 to $170.53 on Tuesday after it said it reached "general agreement" with U.S. and EU regulatory agencies on pathways that could result in accelerated approval of its …

    Published on 5/19/2015
  • COMPANY NEWS: Sarepta to begin submitting rolling NDA for eteplirsen

    Sarepta Therapeutics Inc. (NASDAQ:SRPT) gained $6.23 (38%) to $22.61 in after-hours trading Tuesday on news it held a pre-NDA meeting with FDA and agreed on a rolling NDA submission for eteplirsen (AVI-4658) to treat …

    Published on 5/19/2015
  • COMPANY NEWS: Boehringer acquires Pharmaxis' NASH candidate

    Boehringer Ingelheim GmbH (Ingelheim, Germany) exercised its option to acquire global rights to anti-inflammatory candidate PXS4728A and related molecules from Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY). Boehringer plans to …

    Published on 5/18/2015
  • COMPANY NEWS: EMA picks Pluristem's PLX-PAD for adaptive pathway pilot

    Pluristem Therapeutics Inc. (NASDAQ:PSTI) said its PLX-PAD cells to treat critical limb ischemia (CLI) were selected for EMA's adaptive pathways pilot project.EMA's pathway is intended for programs in Phase I or Phase …

    Published on 5/18/2015
  • COMPANY NEWS: Endo to acquire Par for $8B

    Endo International plc (NASDAQ:ENDP; TSX:ENL) will acquire Par Pharmaceutical Holdings Inc. (Woodcliff Lake, N.J.) from investment firm TPG for about $8 billion, including $6.5 billion in cash and 18 million Endo shares…

    Published on 5/18/2015
  • COMPANY NEWS: Genzyme, Ablynx partner in MS

    Ablynx N.V. (Euronext:ABLX) and the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) partnered to develop Nanobodies against an undisclosed multiple sclerosis target. Ablynx's Nanobodies are therapeutic proteins …

    Published on 5/18/2015
  • COMPANY NEWS: Management tracks

    Endocrine company Chiasma Inc. (Jerusalem, Israel) hired Mark Fitzpatrick as CFO, effective June 10. Fitzpatrick was CFO of rare disease company Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR), where Chief Accounting …

    Published on 5/18/2015
  • COMPANY NEWS: Circassia bids for respiratory plays Aerocrine, Prosonix

    Circassia Pharmaceuticals plc (LSE:CIR) said it intends to acquire a pair of respiratory companies and raise about L275 million ($306.8 million) via a placing and open share offering.Circassia proposed to buy asthma …

    Published on 5/15/2015
  • COMPANY NEWS: Lilly, Sanford-Burnham in autoimmune research deal

    Eli Lilly and Co. (NYSE:LLY) and Sanford-Burnham Medical Research Institute (La Jolla, Calif.) started a research collaboration to develop therapies targeting immune checkpoint modulators to treat autoimmune disorders …

    Published on 5/15/2015
  • COMPANY NEWS: Sorrento rises on NantWorks deal

    Sorrento Therapeutics Inc. (NASDAQ:SRNE) gained $1.51 (13%) to $13.01 on news that its Igdrasol Inc. subsidiary will be acquired by Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.) for $90 million up front.The …

    Published on 5/15/2015
  • COMPANY NEWS: Management tracks

    Biogen Inc. (NASDAQ:BIIB) promoted Matt Griffiths to SVP and chief information officer from VP of pharmaceutical operations and corporate information technology. Infectious disease company VaxInnate Corp. (Cranbury, N.J…

    Published on 5/13/2015
  • COMPANY NEWS: Orexigen continues to sink on Contrave news

    Orexigen Therapeutics Inc. (NASDAQ:OREX) dropped $0.91 (15%) to $5.02 on Wednesday after Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) sent a dispute letter to the company seeking to terminate the companies' collaboration…

    Published on 5/13/2015
  • COMPANY NEWS: Sandoz requests bond from Amgen to cover lost Zarxio sales

    The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) filed a statement with the U.S. Court of Appeals for the Federal Circuit (CAFC) requesting a $179.4 million bond from Amgen Inc. (NASDAQ:AMGN) to compensate for losses…

    Published on 5/13/2015
  • COMPANY NEWS: Baxter buys Sigma-Tau leukemia portfolio

    Baxter International Inc. (NYSE:BAX) acquired a portfolio of leukemia products from Sigma-Tau Group (Pomezia, Italy) for $900 million. The portfolio includes Oncaspar pegasparagase, which is marketed to treat acute …

    Published on 5/12/2015
  • COMPANY NEWS: FDA committee backs Vertex's Orkambi

    FDA's Pulmonary-Allergy Drugs Advisory Committee voted 12-1 on Tuesday that available efficacy and safety data support approval of Orkambi, a combination of lumacaftor (VX-809) and Kalydeco ivacaftor from Vertex …

    Published on 5/12/2015
  • COMPANY NEWS: Lilly, BioNTech in immuno-oncology research deal

    Eli Lilly and Co. (NYSE:LLY) and BioNTech AG (Mainz, Germany) announced a research collaboration to investigate new cancer immunotherapies. The companies will attempt to identify tumor targets and their corresponding T …

    Published on 5/12/2015
  • COMPANY NEWS: Moderna creates rare disease subsidiary Elpidera

    Moderna Therapeutics Inc. (Cambridge, Mass.) launched Elpidera LLC, a subsidiary that will use Moderna's mRNA therapeutics platform to develop treatments for rare diseases. Greg Licholai, former SVP of real-world and …

    Published on 5/12/2015
  • COMPANY NEWS: GSK, UNC partner in HIV, launch newco Qura

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the University of North Carolina partnered to establish a research center at the university's Chapel Hill, N.C., campus and launch newco Qura Therapeutics aimed at curing HIV …

    Published on 5/11/2015
  • COMPANY NEWS: Juno acquires manufacturing play Stage

    Juno Therapeutics Inc. (NASDAQ:JUNO) acquired cell therapy manufacturing company Stage Cell Therapeutics GmbH (Gottingen, Germany) to help produce its chimeric antigen receptor (CAR) and T cell receptor (TCR) therapies.…

    Published on 5/11/2015
  • COMPANY NEWS: Management tracks

    Vaccine play PaxVax Inc. (Redwood City, Calif.) promoted Nima Farzan to CEO from COO; he will remain president. Farzan will replace Kenneth Kelly, who will remain a director.Patient networking company PatientsLikeMe Inc…

    Published on 5/11/2015
  • COMPANY NEWS: Pfizer, AM-Pharma in equity/option deal

    Pfizer Inc. (NYSE:PFE) purchased an equity stake in renal company AM-Pharma B.V. (Bunnik, the Netherlands) and obtained an exclusive option to acquire the remainder of the company. Pfizer can exercise the option when an…

    Published on 5/11/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993